Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3128-3135

  Reid, G ^a   Pel, M E ^a,b   Kirschner, M B ^a   Cheng, Y Y ^a   Mugridge, N ^c   Weiss, J ^c   Williams, M ^a   Wright, C ^a   Edelman, J J B ^d   Vallely, M P ^d   McCaughan, B C ^d   Klebe, S ^e   Brahmbhatt, H ^c   MacDiarmid, J A ^c   van Zandwijk, N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Engeneic Ltd   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Mesothelioma; MicroRNA; Minicells; miR 16

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; MESSENGER RNA; MICRORNA 16; PEMETREXED; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCL 2 GENE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CCND1 GENE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PHARMACOGENETICS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

MESOTHELIOMA; MICRORNA; MINICELLS; MIR-16;

ANIMALS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; RNA INTERFERENCE; TRANSFECTION; TUMOR BURDEN;

EID: 84888785695     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt412     Document Type: Article

References (25)

1. Tsao AS, Wistuba I, Roth JA et al. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-2090.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
3. Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 2011; 73: 256-263.
4. Balatti V, Maniero S, Ferracin M et al. MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. J Thorac Oncol 2011; 6: 844-851.
5. Busacca S, Germano S, De Cecco L et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010; 42: 312-319.
6. Guled M, Lahti L, Lindholm PM et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer 2009; 48: 615-623.
7. Ivanov SV, Goparaju CM, Lopez P et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010; 285: 22809-22817.
8. Kubo T, Toyooka S, Tsukuda K et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 2011; 17: 4965-4974.
9. Pass HI, Goparaju C, Ivanov S et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010; 70: 1916-1924.
10. Kirschner MB, Cheng YY, Badrian B et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 1184-1191.
11. Kao SC, Lee K, Armstrong NJ et al. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology 2011; 43: 128-132.
12. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009; 27: 643-651.
13. MacDiarmid JA, Mugridge NB, Weiss JC et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007; 11: 431-445.
14. Tanaka N, Toyooka S, Soh J et al. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer 2012; 76: 32-38.
15. Bonci D, Coppola V, Musumeci M et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277.
16. Bandi N, Zbinden S, Gugger M et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69: 5553-5559.
17. Bhattacharya R, Nicoloso M, Arvizo R et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 2009; 69: 9090-9095.
18. Wang X, Wang J, Ma H et al. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol 2012; 29: 919-927.
19. Xia L, Zhang D, Du R et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
20. Kunnumakkara AB, Guha S, Krishnan S et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-3861.
21. Gao SM, Yang JJ, Chen CQ et al. Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. J Exp Clin Cancer Res 2012; 31: 27.
22. Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18: 181-187.
23. Sun CY, She XM, Qin Y et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013; 34: 426-435.
24. Kurai J, Chikumi H, Hashimoto K et al. Therapeutic antitumor efficacy of antiepidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Int J Oncol 2012; 41: 1610-1618.
25. Trang P, Wiggins JF, Daige CL et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19: 1116-1122.